
    
      The subjects who have completed the 52-week treatment duration in Study A19-201 will be
      treated with P1101, starting at the dose at Week 50. The dose during this study may be
      increased or decreased up to 500 Î¼g depending on the condition. This study will be continued
      as a post-marketing clinical study after acquisition of the marketing approval of P1101.
    
  